Table 4.
Seriousness and outcome of impaired glucose metabolism events distributed by type of COVID-19 vaccine and reported in Eudravigilance from 1 January 2021 to 11 December 2021.
| Variable | Level | Pfizer–BioNTech Vaccine (n = 2194) |
Moderna Vaccine (n = 638) |
Oxford–AstraZeneca Vaccine (n = 1286) |
Janssen Vaccine (n = 157) |
|---|---|---|---|---|---|
| Seriousness | Caused/Prolonged Hospitalisation (%) | 267 (12.17) | 194 (30.41) | 129 (10.03) | 52 (33.12) |
| Other Medically Important Condition (%) | 761 (34.69) | 117 (18.34) | 506 (39.35) | 45 (28.66) | |
| Life Threatening (%) | 118 (5.38) | 72 (11.29) | 89 (6.92) | 21 (13.38) | |
| Results in Death (%) | 44 (2.01) | 46 (7.21) | 23 (1.79) | 16 (10.19) | |
| Disabling (%) | 91 (4.15) | 27 (4.23) | 69 (5.37) | 5 (3.18) | |
| Congenital Anomaly (%) | 1 (0.05) | 0 (0.00) | 1 (0.08) | 0 (0.00) | |
| Not Serious (%) | 912 (41.57) | 182 (28.53) | 469 (36.47) | 18 (11.46) | |
| Outcome | Recovered/Resolved (%) | 592 (26.98) | 173 (27.12) | 376 (2.24) | 19 (12.10) |
| Recovering/Resolving (%) | 344 (15.68) | 46 (7.21) | 286 (22.24) | 15 (9.55) | |
| Not Recovered/Not Resolved (%) | 523 (23.84) | 171 (26.80) | 347 (26.98) | 63 (40.13) | |
| Fatal (%) | 43 (1.96) | 46 (7.21) | 16 (1.24) | 11 (7.01) | |
| Recovered/Resolved with Sequelae (%) | 69 (3.14) | 3 (0.47) | 19 (1.48) | 1 (0.64) | |
| Unknown (%) | 623 (28.40) | 199 (31.19) | 242 (18.82) | 48 (30.57) |